The Microscopy and Image-analysis Laboratory (MIL) serves as the Morphology Core for the University of Michigan Comprehensive Cancer Center (UMCCC). The MIL was established in 1977 as a University wide shared user microscopy and imaging facility and became a UMCCC Core Facility in 1995. All instrumentation is used on a shared basis by investigators for studies of cell and tissue morphology and ultrastructure. The MIL Is housed and administered within the Department of Cell &Developmental Biology at the University of Michigan Medical School. The Morphology Core offers a cost-effective mechanism for UMCCC researchers to have access to state-of-the-art imaging instrumentation that would not otherwise be available in Individual laboratories because of high acquisition and maintenance costs. Access to highly trained personnel with many years of expertise is also provided by the Morphology Core and is available to all UMCCC members and their staff. The MIL is staffed by a full time manager, a laboratory supervisor, five research associates, and Instrument analyst. Routine histology and electron microscopy sample processing, sectioning, staining, and analysis is available with prior consultation and scheduling. Emphasis Is placed on training the research investigator or their designated staff to properly operate each piece of equipment as needed to meet their imaging research needs.

Public Health Relevance

The use of high-end Imaging instruments have become a standard which research investigators have relied on to understand the mechanisms of disease to combat cancer, in cells and tissues. The UMCCC Morphology Core offers these instruments to our Investigators on a shared use basis as a cost effective mechanism to investigate ongoing funded research projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-25
Application #
8559886
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
25
Fiscal Year
2013
Total Cost
$183,236
Indirect Cost
$80,979
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Manohar, Poorni M; Beesley, Lauren J; Bellile, Emily L et al. (2018) Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer. Clin Nucl Med 43:641-647
Hawley, Sarah T; Li, Yun; An, Lawrence C et al. (2018) Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial. J Clin Oncol 36:659-666
Salami, Simpa S; Hovelson, Daniel H; Kaplan, Jeremy B et al. (2018) Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight 3:
Smith, Joshua; Kulkarni, Aditi; Birkeland, Andrew C et al. (2018) Whole-Exome Sequencing of Sinonasal Small Cell Carcinoma Arising within a Papillary Schneiderian Carcinoma In Situ. Otolaryngol Head Neck Surg 159:859-865
Eberl, Markus; Mangelberger, Doris; Swanson, Jacob B et al. (2018) Tumor Architecture and Notch Signaling Modulate Drug Response in Basal Cell Carcinoma. Cancer Cell 33:229-243.e4
Lazarus, Jenny; Maj, Tomasz; Smith, J Joshua et al. (2018) Spatial and phenotypic immune profiling of metastatic colon cancer. JCI Insight 3:
Kim, Yeung-Hyen; Zhu, Lingqiao; Pyaram, Kalyani et al. (2018) PLZF-expressing CD4 T cells show the characteristics of terminally differentiated effector memory CD4 T cells in humans. Eur J Immunol 48:1255-1257
Davis, Elizabeth J; Griffith, Kent A; Kim, Edward J et al. (2018) A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. Am J Clin Oncol 41:128-132
Mendiratta-Lala, Mishal; Masch, William; Shankar, Prasad R et al. (2018) MR Imaging Evaluation of Hepatocellular Carcinoma Treated with Stereotactic Body Radiation Therapy (SBRT): Long Term Imaging Follow-Up. Int J Radiat Oncol Biol Phys :
Tamura, Shuzo; Wang, Yin; Veeneman, Brendan et al. (2018) Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer. Bladder Cancer 4:77-90

Showing the most recent 10 out of 1493 publications